Protocol Guide • Vitamin B1 • Updated 2026

Thiamine Mega-Dose
Protocol

📄 4 PubMed citations

High-dose Vitamin B1 as used in practitioner protocols, with the small human studies in Alzheimer's and Parkinson's — all 4 forms, dosing tiers, paradoxical reaction warning, and required cofactors.

Inspired by Elliot Overton (@EO_Nutrition) · Clinical studies cited; dosing and protocol details reflect practitioner guidance
53
% mean total UPDRS score improvement in an open-label Parkinson's pilot, no control group (Costantini et al., 2015)
4
Thiamine forms compared: HCl, Benfotiamine, TTFD, Sulbutiamine
77
% less CDR worsening on benfotiamine vs placebo over 12 months, a secondary endpoint (Gibson et al., 2020)

Build your own printable peptide tracker

A personalized injection log, weekly dosing schedule and dated calendar: your compounds filled in, ready to print. Free to build and preview; $5/month to unlock printing.

Stacking compounds? Check interactions first →

Build your tracker →

Evidence at a glanceGraded by study type · every grade linked to a verified PubMed study

BHuman evidence, limited to small trials and pilots
1
A
Human RCT / meta-analysis
2
B
Human, small / pilot
0
C
Animal studies
1
D
Reviews / mechanistic
B
Preliminary findings of high-dose thiamine in dementia of Alzheimer's type
Human, preliminary, 1993 · PMID 8251051 ↑
A
Benfotiamine and Cognitive Decline in Alzheimer's Disease: Results of a Randomized Placebo-Controlled Phase IIa Clinical Trial
Human clinical, 2020 · PMID 33074237 ↑
B
Long-Term Treatment with High-Dose Thiamine in Parkinson Disease: An Open-Label Pilot Study
Human, limited, 2015 · PMID 26505466 ↑
D
Pharmacological thiamine levels as a therapeutic approach in Alzheimer's disease
Mechanistic, 2022 · PMID 36275801 ↑

What we don't have: large or confirmatory trials. The only Grade-A trial is a 70-person randomized placebo-controlled Phase IIa, which its own authors describe as collecting preliminary data. The 1993 Meador study grades B: PubMed indexes it as a randomized controlled trial, but its abstract describes neither randomization nor a placebo arm, its authors present the results as preliminary, and the Gibson 2022 review describes the 1990s high-dose thiamine trials as underpowered with a small number of patients. The Parkinson's data is an open-label pilot with no control group (B). Other grades follow each study's design as stated in its title or abstract — we state the strength plainly instead of implying more.

Why Mega-Dose B1?

Standard thiamine RDA (1.1–1.2mg/day) prevents classic deficiency. Proponents of mega-dosing argue that pharmacological doses act through a different mechanism, outlined below as a hypothesis.

⚡
The "Functional Deficiency" Hypothesis

In this hypothesis, chronic toxicity, oxidative stress, and inflammation inactivate thiamine-dependent enzymes at the cellular level — producing a state called "functional thiamine deficiency" even when blood levels appear normal. Proponents argue that normal dietary intake cannot overcome this enzymatic blockade and that pharmacological doses are needed to restore the affected metabolic pathways; none of the human studies cited on this page tested this. This theory, developed by Dr. Derrick Lonsdale and further popularized by Elliot Overton (EO Nutrition), is offered as the reason high-dose B1 is reported to help across seemingly unrelated conditions — it remains a hypothesis, not an established mechanism.

🔋

Mitochondrial Energy

Thiamine's active form (ThDP) is a coenzyme for the pyruvate dehydrogenase and oxoglutarate (α-ketoglutarate) dehydrogenase complexes, which catalyze essential steps in glucose oxidation (Sambon 2021 review). Practitioners link reduced activity of these enzymes to fatigue and brain fog; the cited studies did not test this.

🧠

Brain & Nerve Function

Thiamine deficiency causes lesions in nerves and brain, and the thiamine-dependent enzyme complexes are needed to make neurotransmitters such as acetylcholine (Sambon 2021 review). The Meador 1993 authors note thiamine's role in acetylcholine metabolism and release; whether mega-dosing restores these pathways in people has not been established.

🛡️

AGE Inhibition

In a 12-month Phase IIa trial in MCI or mild Alzheimer's, benfotiamine significantly reduced increases in blood AGE compared with placebo, an exploratory outcome (Gibson 2020). The proposed mechanism, and any relevance to other conditions, was not tested in the studies cited on this page.

🌿

Autonomic Regulation

Practitioners consider the autonomic nervous system highly thiamine-dependent and use mega-dosing for dysautonomia, POTS, and vagal tone dysregulation. None of the studies cited on this page examined these conditions.

🧬

Gene Expression

Practitioners propose that high-dose thiamine influences gene expression related to energy metabolism, inflammatory cytokines, and oxidative stress; the studies cited on this page did not measure this.

💊

Safety

Thiamine HCl is water-soluble. TTFD is a lipophilic disulfide derivative; benfotiamine is an S-acyl (thioester) derivative that is not itself lipophilic, but is converted in the small intestine to a lipophilic metabolite (Sambon 2021 review). In a 12-month placebo-controlled trial, benfotiamine treatment was reported safe (Gibson 2020). The cited abstracts do not report adverse-event data for multi-gram thiamine HCl dosing.

4 Thiamine Forms + Research-Stage DBT

Practitioners choose a form by target condition. The cited human trials tested only thiamine and benfotiamine, and no trial has compared forms head-to-head.

Form Solubility Bioavailability BBB Crossing (practitioner-reported) Best For Typical Dose (practitioner protocols)
Thiamine HCl Water-soluble Baseline (1×) Limited Baseline form; given orally and intramuscularly in the cited thiamine studies 100–500mg/day
Benfotiamine
Higher than HCl
S-acyl thioester — not itself lipophilic; converted in the gut to a lipophilic metabolite Higher than HCl Moderate Diabetic neuropathy (an early use, per Sambon 2021), smaller rise in blood AGE (exploratory) and Alzheimer's (investigational; Gibson 2020) 150–600mg/day
TTFD
CNS focus
Lipophilic (disulfide) Not quantified in cited studies High (practitioner-reported) Practitioner use: brain/CNS, autonomic symptoms, fatigue (not tested in the cited human trials) 25–100mg/day
Sulbutiamine
Nootropic
Lipophilic (synthetic disulfide) Not measured in cited studies Not measured in cited studies Sold as a nootropic — not tested in any study cited on this page Not established in cited studies
Dibenzoylthiamine (DBT) Lipophilic (thioester) Higher than HCl (not quantified in cited studies) Not measured in cited studies Research stage only — more anti-inflammatory than benfotiamine in in vitro studies (Sambon 2021) TBD
💡
Practitioner Tip: Stack TTFD + Benfotiamine

Some practitioner protocols combine TTFD (favored for CNS use) with benfotiamine (favored for peripheral nerves and AGE inhibition), starting benfotiamine alone to assess tolerance, then introducing TTFD at a low dose (25mg) before titrating up. The intended rationale is complementary tissue coverage; no cited study tested the combination.

Which Thiamine Form Should You Buy?

Practitioner uses and the cited evidence, summarized from the comparison above — then pick it up below.

Form Best For Key Trait Buy
Benfotiamine Peripheral nerves (practitioner use), smaller rise in blood AGE (exploratory; Gibson 2020) and Alzheimer's (investigational; Phase IIa primary endpoint not significant) S-acyl derivative; higher bioavailability than HCl (Sambon 2021 review) Shop →
TTFD (Allithiamine) Practitioner use: brain/CNS, autonomic symptoms, fatigue (not tested in the cited human trials) Favored for CNS use in practitioner protocols — reportedly more prone to the paradoxical reaction Shop →
Sulbutiamine Sold as a nootropic (not tested in the studies cited here) Synthetic lipophilic B1 derivative Shop →
Thiamine HCl Cheap baseline / stacking for higher total thiamine load Water-soluble base form; lowest cost Shop →

Bioavailability & CNS Penetration

A qualitative comparison; bar lengths are illustrative, not data. The plasma ordering of HCl, benfotiamine and TTFD follows the Sambon 2021 review; everything else, including all blood-brain-barrier tiers, is practitioner-reported and was not measured in humans in the studies cited on this page.

📊 Plasma Bioavailability (qualitative)
Thiamine HCl
1× (baseline)
Benfotiamine
Higher than HCl
TTFD
Higher than HCl; ranked below benfotiamine in the Sambon 2021 review
Sulbutiamine
Not measured in cited studies
🧠 Blood-Brain Barrier Penetration (qualitative, practitioner-reported)
Thiamine HCl
Poor — limited at high dose
Benfotiamine
Moderate — good peripheral
TTFD
High — practitioner-reported, not measured in cited studies
Sulbutiamine
Not measured in cited studies

Start Low, Go Slow

The Overton/Lonsdale framework for escalating thiamine dosing — always with cofactors in place first. Practitioners report wide individual variation and treat slow titration as essential.

T1

Phase 1: Foundation (Weeks 1–2)

Establish cofactor base before starting thiamine. Practitioners use this phase to lower the risk of paradoxical reactions and support enzymatic conversion; the cited studies did not test it.

Magnesium glycinate 200mg/day + B-Complex + Potassium (dietary)
T2

Phase 2: Low Dose Start (Weeks 3–4)

Introduce thiamine at lowest effective dose. Monitor for paradoxical reaction (fatigue, anxiety, tachycardia, insomnia). If symptoms worsen, hold and ensure cofactors are adequate.

Benfotiamine 100–150mg/day OR TTFD 25–50mg/day (not both initially)
T3

Phase 3: Therapeutic Titration (Weeks 5–12)

Gradually increase dose every 1–2 weeks while monitoring symptoms. May add Thiamine HCl for higher total thiamine load.

Benfotiamine 300–600mg/day OR TTFD 50–100mg/day + HCl 100–500mg
T4

Phase 4: Maintenance / High Protocol

Practitioner protocols for serious neurological conditions (Parkinson's, Alzheimer's), typically supervised. The cited Parkinson's study (Costantini 2015) used 100 mg intramuscular thiamine twice a week; the cited oral Alzheimer's study (Meador 1993) used 3–8 g/day. Sustain cofactors throughout.

Thiamine HCl 500mg–4g/day (supervised) + benfotiamine 300–600mg + cofactors

The Paradoxical Reaction

Practitioners flag this as the key thing to understand before mega-dosing, and as a reason some people stop early.

⚠️ Paradoxical Worsening (Practitioner-Reported)

Practitioners report that some individuals experience a temporary worsening of symptoms when starting or increasing thiamine. This can manifest as increased fatigue, brain fog, anxiety, heart palpitations, insomnia, or general malaise. It is commonly attributed to a metabolic adjustment as cells ramp up ATP production, but this mechanism has not been established in clinical studies — new palpitations or other significant symptoms are a reason to stop and talk to a clinician. Practitioner reports describe the reaction as more common with TTFD than benfotiamine (not measured in the cited studies), which is why some practitioner protocols start low on benfotiamine (Shop →) before adding TTFD.

🔍

Why It Happens

The proposed explanation (not established in clinical studies): restoring oxidative energy metabolism suddenly increases metabolic demand for cofactors (especially magnesium). A temporary "nutritional debt" is called in. Proponents also suggest that rapid restoration of autonomic nerve function may trigger transient dysautonomia symptoms.

🩺

How Practitioners Manage It

If reaction occurs: Hold dose for 1 week. Increase magnesium to 300–400mg/day. Ensure complete B-complex coverage. Resume at 50% of last dose. Titrate more slowly. If symptoms are severe or persist, stop and consult a clinician.

📝
Start-Low-Go-Slow Is Not Optional

Overton's protocol specifically warns against starting at high doses. Starting low (for example, 25mg TTFD or 100mg benfotiamine) rather than at therapeutic doses is intended to reduce paradoxical reaction severity — a practitioner rationale that none of the studies cited on this page tested.

What B1 Needs to Work

Practitioner protocols treat these cofactors as prerequisites rather than optional add-ons. The clinical studies cited on this page did not test cofactor co-administration; the doses shown are practitioner-protocol ranges, not tested targets.

🔴 Magnesium
200–400mg/day (glycinate or malate)
CRITICAL in practitioner protocols, which cite magnesium as a cofactor for TPK (thiamine pyrophosphokinase), the enzyme that converts thiamine → ThDP (the active coenzyme form); the cited studies did not test magnesium co-administration. Practitioners start Mg 2 weeks BEFORE thiamine. Shop →
🔴 B-Complex
Full-spectrum B-complex, 1–2×/day
CRITICAL in practitioner protocols. Thiamine works alongside the other B vitamins — especially B2 (riboflavin), B3 (niacin), and B6. Practitioner protocols add a B-complex as a precaution against imbalances in other B vitamins during high-dose thiamine use; a high-quality B-complex is meant to guard against secondary deficiencies. Shop →
🟡 Potassium
Dietary first, or 200–400mg supplement
Practitioner rationale (not tested in the cited studies): as cellular metabolism ramps up, cells may take up more K+, similar to refeeding syndrome, and low potassium can mimic or worsen paradoxical reactions. Priority: dietary potassium (avocados, bananas, potatoes, leafy greens) over supplementation.
🩵 Alpha-Lipoic Acid
100–300mg/day
Practitioners pair ALA with thiamine because both act in the pyruvate dehydrogenase complex, and often pair it with benfotiamine in neuropathy protocols; the cited studies did not test it.
🩵 Acetyl-L-Carnitine
500–1000mg/day
Included in practitioner protocols for mitochondrial support (carnitine carries fatty acids into mitochondria) and often paired with benfotiamine in neuropathy protocols; the cited studies did not test it.
🩵 Zinc
15–25mg/day (not with high-dose copper)
Included in practitioner protocols as a general enzymatic cofactor; the cited studies did not test zinc co-administration.

What the Research Shows

The four sources graded in Evidence at a glance (three human trials and one review), plus one ungraded background review on thiamine precursors (Sambon 2021).

Long-Term Treatment with High-Dose Thiamine in Parkinson Disease: An Open-Label Pilot Study
2015
Costantini A, Pala MI, Grossi E, Mondonico S, Cardelli LE, Jenner C, Proietti S, Colangeli M, Fancellu R. | J Altern Complement Med. 2015 Dec;21(12):740-7. | PMID: 26505466
Key finding: 50 PD patients treated with 100 mg thiamine administered intramuscularly twice a week (open-label, no placebo group). Mean UPDRS scores improved from 38.55 ± 15.24 to 18.16 ± 15.08 (p = 2.4 × 10⁻¹⁴) — approximately 53% improvement within 3 months.
↗ PubMed PMID: 26505466
Benfotiamine and Cognitive Decline in Alzheimer's Disease: Results of a Randomized Placebo-Controlled Phase IIa Clinical Trial
2020
Gibson GE, Luchsinger JA, Cirio R, et al. | J Alzheimers Dis. 2020;78(3):989-1010. | DOI: 10.3233/JAD-200896 | PMID: 33074237
Key finding: 12-month placebo-controlled Phase IIa trial of benfotiamine 600mg/day in 70 patients with amnestic MCI or mild Alzheimer's. The rise in ADAS-Cog (cognitive decline) was 43% lower in the benfotiamine group vs. placebo, though this primary endpoint was only near-significant (p = 0.125). Worsening on the CDR was 77% lower (p = 0.034), increases in advanced glycation end-products were significantly reduced (p = 0.044), and an FDG-PET pattern score showed a treatment effect (p = 0.002). Benfotiamine was safe and well tolerated.
↗ PubMed PMID: 33074237
Preliminary Findings of High-Dose Thiamine in Dementia of Alzheimer's Type
1993
Meador K, Loring D, Nichols M, et al. | J Geriatr Psychiatry Neurol. 1993;6(4):222-9. | PMID: 8251051
Key finding: Small early study using oral thiamine 3–8g/day in Alzheimer's patients. The authors present the results as preliminary, suggesting thiamine at these pharmacologic dosages may have a mild beneficial effect in dementia of Alzheimer's type. The authors concluded the findings warrant further investigation.
↗ PubMed PMID: 8251051
Pharmacological Thiamine Levels as a Therapeutic Approach in Alzheimer's Disease
2022
Gibson GE, Feldman HH, Zhang S, Flowers SA, Luchsinger JA. | Front Med (Lausanne). 2022;9:1033272. | DOI: 10.3389/fmed.2022.1033272
Key finding: Review synthesizing evidence for pharmacological thiamine in AD. The review notes that activities of thiamine-dependent enzymes are reduced in the brains of patients with AD; that in transgenic mice benfotiamine reduces plaque formation and improves memory in a dose-dependent manner; and that in the streptozotocin (STZ) rodent model of AD, benfotiamine reverses inflammation. The authors describe the 2020 Phase IIa pilot as showing potential efficacy and call for further research.
↗ Frontiers in Medicine
Neuroprotective Effects of Thiamine and Precursors with Higher Bioavailability: Focus on Benfotiamine and Dibenzoylthiamine
2021
Sambon M, Wins P, Bettendorff L. | Int J Mol Sci. 2021;22(11):5418. | PMC8196556
Key finding: Background review (not graded) of thiamine precursors developed to overcome thiamine's slow, carrier-mediated absorption. It distinguishes benfotiamine, an S-acyl thioester that is not itself lipophilic but is dephosphorylated in the small intestine to a lipophilic metabolite, from the uncharged, hydrophobic disulfide precursors (allithiamine, TTFD, sulbutiamine), and states that benfotiamine has higher bioavailability than thiamine, thiamine disulfide or TTFD. It notes the benefits seen in an Alzheimer's mouse model were specific to benfotiamine and not seen with TTFD or high-dose thiamine, and that in vitro studies found dibenzoylthiamine (DBT) more anti-inflammatory than benfotiamine.
↗ PMC8196556

Morning / Evening Split

Sample practitioner-style maintenance schedule (Phase 3+); not tested in the cited studies. Adjust doses based on individual response and form selection.

🌅 Morning (with breakfast)
Benfotiamine 300mg — taken with breakfast in this sample schedule
TTFD 50mg — start lower; favored for CNS use in practitioner protocols
Magnesium glycinate 200mg — morning cofactor dose
B-Complex (1 capsule) — full B vitamin coverage
Alpha-Lipoic Acid 200mg — often paired with B1 in practitioner protocols
Zinc 15mg — practitioner-listed cofactor
🌙 Evening (with dinner)
Benfotiamine 300mg — second daily dose
Thiamine HCl 250mg — optional for higher total thiamine load
Magnesium glycinate 200mg — evening dose
Acetyl-L-Carnitine 500mg — evening dose
Potassium 200mg — if dietary sources are low
⚠️ TTFD timing — practitioners often schedule it earlier in the day (anecdotal; not tested in the cited studies)
💰
Estimated Monthly Cost

Rough retail estimates; prices vary. Benfotiamine 600mg/day: ~$25–35/mo | TTFD 50mg/day (Thiamax): ~$35–50/mo | Magnesium glycinate: ~$15/mo | B-Complex: ~$10/mo | ALA 200mg: ~$12/mo | Sum of these five items: approximately $97–122/month (optional schedule items not included).

Key Takeaways

What the Evidence Supports

  • In an open-label Parkinson's pilot with no control group, intramuscular high-dose thiamine was followed by improved scores (total UPDRS ~53% lower, motor part III ~55% lower; Costantini 2015)
  • In a 70-person Phase IIa RCT in amnestic MCI or mild Alzheimer's, benfotiamine's primary endpoint (ADAS-Cog rise 43% lower vs placebo) was not statistically significant (p = 0.125); the secondary CDR endpoint worsened 77% less (p = 0.034) (Gibson 2020)
  • Benfotiamine treatment was reported safe over 12 months in an Alzheimer's Phase IIa RCT (Gibson 2020)

Limitations & Unknowns

  • Most thiamine neuroprotection studies are small, open-label, or pilot stage — Phase III RCTs needed
  • Optimal dosing for specific conditions is not yet standardized
  • Paradoxical reactions are described in practitioner reports, sometimes as severe; their frequency and severity have not been measured in the cited studies
  • Anecdotal reports of sulbutiamine tolerance lead some users to cycle it rather than take it daily long-term; this has not been well studied
  • Dibenzoylthiamine is research-stage; the cited review reports only in vitro and mouse data
  • No head-to-head comparison trials between thiamine forms for neurological endpoints
  • Mechanism of paradoxical reaction not fully elucidated in clinical literature
  • The "functional deficiency" explanation is a hypothesis — the Parkinson's pilot authors propose a thiamine-dependent metabolic dysfunction, but it has not been established
  • TTFD's reputation for superior CNS penetration rests on practitioner sources; none of the cited human trials tested TTFD
  • Start-low-go-slow titration and cofactor priming (magnesium, B-complex, potassium) are practitioner recommendations; no cited study has tested them

Want the Complete Protocol Guide?

Dosing schedules, interaction warnings, and cycle protocols for 20+ compounds, all in one place.


Get the Guide: $19 (normally $29) →
The Peptide Buyer’s Playbook ($19)
Ebook
The Complete Peptide Protocol Guide

67-page guide: protocols, dosing, sourcing. Everything in one place.

Get the guide: $19 (normally $29) → The Peptide Buyer’s Playbook ($19) All ebooks & guides →
📘

Get the Free 2026 Peptide Protocol Stack

Twelve compounds across four pillars: metabolic, tissue repair, longevity, cognitive. Citations included, formatted to print. Sent straight to your inbox.

Educational Disclaimer: This page is for educational and informational purposes only. It is not medical advice. Thiamine (Vitamin B1) and its derivatives are dietary supplements in the United States. High-dose thiamine protocols described on this page reflect practitioner protocols rather than the cited studies; they are not FDA-approved treatments for any disease. Always consult with a qualified healthcare provider before beginning any supplementation protocol, especially if you have a neurological condition or are taking medications. Individual responses vary significantly. Clinical study results on this page come from the peer-reviewed sources cited above; dosing tiers, form comparisons, cofactor guidance, and paradoxical-reaction management reflect practitioner protocols (Lonsdale/Overton) and were not established by those studies.